Neurological Pattern Reference

Personal Reference — Laurel Fitzhugh Initial capture: May 2026 | Updated: May 19, 2026 Status: Draft — incomplete, requires updating as new information develops

I. The Central Question

A primary neurological or systemic vascular condition — possibly antiphospholipid syndrome, possibly a heritable connective tissue vasculopathy, possibly both — may have been present since early adulthood or before, expressing itself across multiple systems simultaneously. The current diagnostic picture (seropositive RA, fibromyalgia, cryptogenic strokes, intracranial aneurysms) may represent downstream expressions of this upstream condition rather than independent co-occurring diseases.

This hypothesis has never been formally evaluated. The purpose of neurology consultation is to determine whether a unified diagnosis exists and what workup is required to establish or exclude it.

II. The Chronological Picture

Pre-2000 Paternal family: multiple siblings with palmar erythema; one brother with RA; one brother with recurring verbal and motor tic disorder; brothers raised in petrochemical refinery environment in East Texas. Father: anosmia to refinery chemicals, indicating lifelong exposure. GSTP1 A/G variant (reduced detoxification capacity) may reflect transgenerational petrochemical exposure effects.

Early Childhood Continuous antibiotic exposure infancy through age 7 for recurrent ear infections. Severe enough to produce chronic mastoiditis — structural finding visible on brain imaging from 2016 through 2025. Developmentally significant microbiome disruption during CNS maturation window.

~2000 Widespread pain and fatigue diagnosed as fibromyalgia. Fibromyalgia diagnosis likely a placeholder — tender point criteria not clearly met. Retrospective hypothesis: symptoms may represent central sensitization from subclinical CNS small vessel disease, now confirmed as present from at least 2016 and likely earlier. Predates RA diagnosis by approximately 8 years.

Early-to-mid 2000s (pre-2008) Pregabalin prescribed for fibromyalgia/pain. Produced sudden loss of postural tone without warning — clinically consistent with pregabalin-induced negative myoclonus, a cortical inhibitory phenomenon. Resolved within days of discontinuation. Earliest documented evidence of neurological vulnerability, predating RA diagnosis, all biologic exposure, and the strokes. The posterior circulation architecture subsequently documented on imaging — diminutive vertebrobasilar system dependent on a single fetal vessel — means posterior circulation insufficiency was a structural vulnerability present throughout this period.

2008 Seropositive RA diagnosed. Methotrexate: reaction began within days of first dose — severe peripheral neuropathy plus unprecedented psychiatric presentation; resolved rapidly and completely after discontinuation; severity substantially exceeded standard low-dose methotrexate expectations.

2008–2018 Consistent pharmacological phenotype across drug classes: complete non-response or amplified neurological reaction, with no middle ground. Pattern reflects constitutionally compromised nervous system responding predictably, not idiosyncratic drug sensitivity. Each neurologically active drug that produced a reaction was an additional CNS insult on an already compromised system.

June 2016 — First Stroke and Baseline Vascular Imaging Left temporal lobe acute ischemic infarct (1.5 x 2.8 cm); cryptogenic. Extensive embolic source workup negative: carotid duplex (no significant stenosis), transthoracic echo (normal), TEE June 2017 (no cardioembolic substrates, no PFO, bubble study negative), abdominal aortic ultrasound (no aneurysm), serial cardiac follow-up through 2021 — no embolic source identified. MRI same date: small vessel disease already present — “few small scattered foci compatible with minor small vessel ischemic change” — predating the stroke event; this is the earliest documented evidence of small vessel CNS disease. MRA same date (first cerebrovascular imaging ever obtained): diminutive vertebrobasilar system; posterior circulation primarily supplied by ectatic right persistent trigeminal artery; 4mm right cavernous ICA aneurysm; probable 2mm left MCA branch aneurysm. Constitutional vascular architecture fully present at baseline — not acquired during surveillance.

June 2017 Neuropsychological evaluation by Dr. Tricia Merkley, Barrow (full report on file). Above-average baseline confirmed: Full Scale IQ 126 (96th percentile), Verbal Comprehension 132 (98th percentile), Working Memory 131 (98th percentile). Moderate left hand motor impairment documented and flagged as inconsistent with left temporal stroke location. Right hemisphere dysfunction may have been present and progressive before the 2018 stroke — one year before the right insular event. One-day episode of memory disturbance and repetitive thinking noted in this period, attributed to statin side effects at the time; in retrospect, a possible minor vascular event in someone with bilateral progressive small vessel disease between two cryptogenic strokes. The 2017 MRA was focused on the aneurysm and read as normal parenchyma; it was not specifically evaluating for right hemisphere small vessel changes. No follow-up neuropsychological evaluation has been performed since.

Note on cognitive reserve and masking: the exceptional baseline documented in 2017 has masked functional losses from clinical view throughout this history. Compensation at this cognitive level makes deficits invisible against population norms. Strokes that would have produced visible sequelae in most patients produced none that were clinically apparent. A current neuropsychological evaluation compared against the 2017 individual baseline — not population norms — will reveal losses that the clinical picture currently underrepresents. This is the primary reason re-evaluation is urgent rather than merely indicated.

May 2018 — Pre-Stroke Neurological Event ER visit for headache, CT head normal. Two months before the second stroke; headache in a patient with a known growing intracranial aneurysm warrants noting as a pre-stroke neurological event in the pattern.

July 2018 — Second Stroke Right insular cortical CVA extending to frontal operculum; cryptogenic — second unexplained stroke. Right insula is primary autonomic integration center; sequelae have never been formally evaluated. Attending cardiologist concluded the stroke appeared potentially related to the growing right ICA aneurysm — a vasculopathic rather than embolic interpretation. CTA same date: right cavernous ICA aneurysm now 6mm — grown from 4mm at 2016 baseline. MRI July 19, 2018: “Chronic small vessel ischemic changes are mild in the juxtacortical and deep white matter of both cerebral hemispheres diffusely” — bilateral distribution is critical: neither the left temporal nor the right insular stroke location explains bilateral white matter changes; this is independent evidence of a diffuse process, not stroke-related damage. MRA July 19, 2018: trigeminal artery confirmed as dominant posterior supply; vertebral arteries and proximal basilar hypoplastic; right ICA aneurysm 5.5mm.

December 2022 Antiphospholipid antibody panel: anticardiolipin IgM 21 (normal <13) — elevated; beta-2 glycoprotein I IgM 63 (normal <33) — markedly elevated; remaining three antibodies negative. Confirmatory testing was never performed. Results were never communicated to Barrow neurology. Open and urgent diagnostic question in context of two cryptogenic strokes.

2023–2024 — Aneurysm Treatment and Neurological Events March 2023: right cavernous ICA aneurysm now approximately 1.2cm — dramatic growth from 6mm in 2018. May 2023: Pipeline embolization, successful. January 2024: ER stroke evaluation — neurological event occurred between the two iron infusions that triggered the 2024 systemic escalation. May 2024: hospitalization for severe balance disorder — unable to walk; stroke evaluation; occurred during documented B12 injection gap. MRI May 2024: “Hyperintense T2 and FLAIR signal greatest in posterior right frontal region, likely due to microvascular disease” — more extensive than 2016, specifically localized adjacent to motor and autonomic pathways.

July 2025 — Confirmed Structural CNS Damage MRI with contrast: encephalomalacia confirmed right insula posteriorly — permanent structural tissue loss at primary CNS autonomic integration site. Small vessel disease “slightly increased from prior MRI July 19, 2018” — confirmed ongoing progression.

Late 2025–Early 2026 — HCQ Vestibular Crisis Daily hydroxychloroquine initiated mid-to-late December 2025 following months of deliberate resistance to provider recommendation. Acute vestibular crisis developed within days to two weeks of daily dosing — presentation indistinguishable from major stroke, inability to stand, emergency services called. Self-discontinued upon recognizing the connection approximately December 30 or early January 2026. Allergy formally documented January 13, 2026. Residual vestibular and balance damage did not fully resolve. B12 requirement escalated from twice weekly to daily methylcobalamin following this event; daily injections now insufficient.

May 2026 — Current Acute Neurological Escalation Escalation of baseline neurological symptoms crossing threshold for prednisone intervention — conservative marker given PRN-only approach and high threshold for pharmaceutical use. Symptoms included cognitive fog, loss of executive function, and word retrieval failure substantially worse than chronic baseline impairment in these domains; proprioceptive balance disturbance severe enough to require active conscious compensation for walking; anxiety and psychological overwhelm component qualitatively atypical and distinct from usual pattern, suggesting autonomic or limbic involvement beyond the cognitive and motor picture. Partial response to prednisone within hours, consistent with documented pharmacological phenotype of faster-than-expected onset. Residual proprioceptive deficit and word retrieval impairment persisted after inflammatory component partially resolved, consistent with structural substrate underlying the acute episode.

The Small Vessel Disease Progression — Summary

Four imaging time points document progressive small vessel CNS disease:

• 2016: present at first stroke imaging, predating the acute event
• 2018: bilateral at time of second stroke — “both cerebral hemispheres diffusely” — independent of either infarct location, confirming diffuse process
• 2024: more extensive, posterior right frontal predominance, adjacent to motor and autonomic pathways
• 2025: confirmed progression from 2018 baseline

The small vessel disease predates both strokes, was bilateral at the time of the second stroke, and has continued progressing through and after them. The bilateral 2018 distribution is the strongest imaging evidence that this is a constitutional diffuse process rather than stroke-related focal damage.

The Vestibular and Balance System — Cumulative Insult Pattern

The balance and vestibular system reflects a stepwise permanent worsening that cannot be attributed to any single event. The cumulative sequence:

Constitutional terrain — genetic vulnerability, early developmental disruption, and years of undiagnosed pernicious anemia producing demyelination across vagal, cerebellar, and vestibular pathways before any treatment began.

Suboptimal B12 management — years of hydroxocobalamin rather than methylcobalamin, reactive rather than prophylactic dosing, and documented compliance gaps — maintained partial but never full remyelination.

Right insular stroke 2018 — direct structural damage to primary CNS autonomic and postural integration site, confirmed as permanent on 2025 MRI.

Hydroxychloroquine vestibular crisis late 2025/early 2026 — acute vestibular damage of sufficient severity to prompt emergency services, with presentation indistinguishable from major stroke and inability to stand; damage did not fully reverse; B12 requirement escalated permanently following this event.

B12 compliance gaps — particularly spring 2024 when injections were stopped during hives investigation; acute demyelination on an already compromised system, partially recovered but not fully.

Each insult reduced the baseline. None fully reversed. Current balance function reflects the accumulated total, not any single event. The current functional baseline is permanently lower than pre-2024 and continues to decline. Proprioceptive function now requires increasing conscious effort and compensation for routine ambulation, with intermittent gait abnormality.

The B12 deficiency demyelination and the vascular small vessel disease are distinct contributors to the white matter picture — both are present, both progressing, and standard imaging reads have not distinguished between them. This distinction has clinical implications: vascular small vessel disease is largely irreversible; demyelination from B12 deficiency is at least partially reversible with adequate sustained repletion.

HPA Axis Dysregulation

Absent classic morning stiffness pattern — the typical RA morning gel phenomenon driven by overnight cortisol nadir and inflammatory surge. Absence of this pattern suggests a flattened or blunted diurnal cortisol rhythm rather than normal HPA cycling. Consistent with adrenal insufficiency or HPA axis dysregulation. Low-dose hydrocortisone three times daily initiated — framed as physiologic replacement of a flattened diurnal rhythm rather than pharmacological inflammation suppression.

HPA axis function depends on intact central regulatory capacity including insular and limbic input to the hypothalamus. Documented insular damage and progressive small vessel CNS disease affecting autonomic pathways are consistent with CNS-origin HPA dysregulation as a contributing or primary factor, rather than purely peripheral adrenal insufficiency. This distinction has not been formally evaluated and represents an open diagnostic question.

III. The Unified Vasculopathy Hypothesis

A primary hypercoagulable and autoimmune vascular state has been present since early adulthood or before, operating through two simultaneous mechanisms:

First: progressive subclinical CNS small vessel disease — confirmed on imaging as predating the 2016 stroke, bilateral at the time of the second stroke, and progressing continuously. Producing functional neurological effects for years before the strokes declared themselves: altered pain processing, neurological drug sensitivity, the pregabalin episodes, the unexplained left hand finding in 2017.

Second: creating conditions for thrombotic events — the strokes as acute visible expressions of a chronic vascular process, not discrete random embolic events. Comprehensive cardiac embolic source evaluation including TEE with bubble study found no embolic substrate, strengthening the intrinsic cerebrovascular explanation.

The aneurysms fit this picture: the right ICA aneurysm grew most rapidly during the period of worst inflammatory activity. The trigeminal artery ectasia was present at first imaging — suggesting it is constitutional rather than acquired from hemodynamic stress.

The constitutional vascular architecture was fully present at the first available imaging in 2016, with no prior comparisons available. It predates all documented pathology.

The right insular stroke produced permanent structural tissue loss — confirmed on 2025 MRI — at the primary CNS site of autonomic integration. This is not historical. It is documented, permanent damage to the system responsible for modulating the inflammatory response driving the entire clinical picture.

IV. Genetic Findings (23andMe, partial — fresh analysis pending)

Not yet assessed: Prothrombin G20210A (rs1799963) — requires clinical blood test. PTPN22 rs2476601 — not genotyped. COL3A1 and other vascular connective tissue genes. Full fresh Promethease analysis pending.

Family genetic data: 23andMe/Ancestry raw data available across approximately 3 generations, 8-10 family members. Promethease analysis planned. Highest priority: brother with tic disorder (paternal line neurological clustering); maternal line members with stroke history. Target variants for comparison: rs7574865, rs4963128, rs5918, rs4880, rs1695, rs1801131, HLA-B27 markers.

Summary: two independent genetic signals pointing toward APS susceptibility. Homozygous platelet hyperactivatability combining with documented thrombocytosis. Seropositive RA carries approximately 28% prevalence of antiphospholipid antibodies — placing the December 2022 findings in a population already at elevated baseline risk.

V. Family History — Vascular and Autoimmune Pattern

Paternal line: Multiple brothers with palmar erythema; raised in East Texas petrochemical refinery environment. One brother with RA. One brother with recurring verbal and motor tic disorder — uninvestigated and undiagnosed. Father: anosmia to refinery chemicals; palmar erythema pattern. Whether the paternal clustering reflects heritable genetic tendency, transgenerational epigenetic effects of chronic petrochemical exposure, or both is not resolvable from available evidence.

Maternal line: Mother — multiple strokes over final 8-10 years of life; colon cancer. Sisters: celiac disease, Stage IV COPD, RA.

Pattern: Autoimmune and vascular disease clustering across both family lines. Paternal line shows vascular and palmar erythema clustering consistent with heritable constitutional tendency. Maternal line shows stroke burden and autoimmune clustering.

VI. Outstanding Diagnostic Questions

Urgent — directly relevant to ongoing stroke risk:

Antiphospholipid syndrome confirmation — repeat antibody panel required. Single draw from December 2022 never confirmed. Two cryptogenic strokes with unconfirmed elevated APS antibodies represents an open thrombotic risk. Comprehensive cardiac embolic source workup including TEE with bubble study was negative — APS remains the most coherent unconfirmed explanation.

Prothrombin G20210A — not covered by 23andMe; requires clinical blood test.

JAK2 V617F mutation — somatic mutation requires clinical blood test. Decades of thrombocytosis has never been evaluated as primary vs. reactive.

Important — relevant to diagnostic reframing:

Right insular stroke sequelae — never formally evaluated despite confirmed permanent structural damage. Right insula involved in autonomic regulation, interoception, pain processing, HPA axis modulation.

Neuropsychological re-evaluation — no assessment since June 2017, predating the 2018 stroke, the HCQ vestibular crisis, the 2024 dysbiosis escalation, and all subsequent neurological events. The 2017 report documents an exceptional individual baseline. Re-evaluation must be interpreted against that individual baseline, not population norms — deficits invisible against population averages will be measurable against the documented 2017 ceiling.

Distinction between vascular and demyelinating white matter disease — standard imaging reads have not separated these two contributors. Vascular small vessel disease is largely irreversible; demyelination from B12 deficiency is at least partially reversible with adequate sustained repletion. The distinction has direct clinical implications.

HPA axis dysregulation — possible CNS-origin etiology given insular and hypothalamic pathway compromise; not yet formally evaluated. Distinguish from peripheral adrenal insufficiency.

HLA-B27 clinical implications — carrier status documented genetically; never formally assessed for spondyloarthropathy component alongside RA diagnosis.

Mitochondrial workup — never performed despite consistent multi-system pattern and SOD2 genetic variant.

Lower priority:

CNS vasculitis or autoimmune encephalopathy panel — specific antibody panels never ordered.

Full connective tissue genetic assessment — COL3A1, COL5A1, ACTA2, FBN1 not yet evaluated.

Targeted re-review of 2017 imaging — specifically for right hemisphere small vessel changes not the focus of the original read.

2mm trigeminal artery aneurysm surveillance — saccular outpouching abutting ventral pons, stable since 2018; location warrants explicit discussion of surveillance thresholds.

CNS mast cell involvement — given compromised BBB and resident CNS mast cell population, the systemic mast cell escalation since 2024 may have a neuroinflammatory component that has never been assessed.

VII. Open Questions and Unknowns

Whether the fibromyalgia symptoms (~2000) represent central sensitization from subclinical CNS small vessel disease — now confirmed as present from at least 2016 — or a separate primary process.

Whether the right hemisphere dysfunction documented indirectly in 2017 represents a progressive process already underway or a discrete pre-stroke event.

Whether APS, if confirmed, is primary or secondary to another autoimmune condition.

Lupus or undifferentiated connective tissue disease has never been formally evaluated as a unifying diagnosis.

Whether the small vessel disease visible on 2016 imaging was present earlier — and if so, whether it was the substrate for the pregabalin episodes and early fibromyalgia symptoms.

Whether the white matter changes in the 2024 hospitalization period reflect primarily vascular progression, B12 deficiency demyelination during the injection gap, or both — and to what degree the demyelinating component has recovered with restored B12 repletion.

Whether the current permanently lowered vestibular and balance baseline has a recoverable demyelinating component that optimized methylcobalamin management could partially address.

Whether the 1-day cognitive episode in 2017 between strokes represents a third minor vascular event.

Whether the HPA axis dysregulation reflects CNS-origin regulatory failure from insular and hypothalamic pathway compromise, peripheral adrenal insufficiency, or both.

VIII. Possible Signals — Undetermined Clinical Significance

The following observations are noted for the record. Each is real and worth flagging for clinical attention. None has been formally evaluated, and the interpretive frameworks suggested are hypothetical. Where a finding might fit into the established analytical picture is noted, but this placement is speculative.

Peripheral vagal dysfunction cluster Weak gag reflex (documented, St. Joseph’s problem list 2019). Intermittent swallowing dysfunction with occasional aspiration (observed). Persistent single dry reflexive cough of unclear onset duration (observed). Hoarseness following March 2026 angioedema episode, not fully resolved (observed; laryngeal involvement in that episode is documented). These findings are individually noted but their collective significance is undetermined. If they collectively represent peripheral vagal neuropathy, they would add a peripheral dimension to the central vagal deficit documented in the SetPoint mechanistic reference.

Autonomic afferent signals Tinnitus previously flare-associated, now continuous (observed progression; tinnitus itself documented in health history). Bladder sensory dysregulation — persistent urinary sensations without infection, pain, or escalation; UA negative May 19, 2026, infectious etiology excluded (observed). If these represent aberrant autonomic afferent signaling, they would be consistent with the broader autonomic dysfunction picture.

Family neurological observations — hypothetical signals Mother’s fall mechanism: leaning far back to swallow medications, continuing to fall, resulting in hip fracture. Mechanism possibly consistent with sudden postural tone loss rather than simple balance failure — relevant in the context of the patient’s own pregabalin-induced postural tone episodes. Undetermined; could reflect age-related balance decline.

Paternal brother’s tic disorder may include a single dry reflexive cough matching the patient’s presentation — pending confirmation from sibling. If confirmed, possible heritable neurological signal in a family line with documented vascular and autoimmune clustering.

Integrated Constitutional Systems Model:
This document reflects current systems-level interpretation, mechanistic analysis, and working hypotheses based on documented history, longitudinal patterns, imaging, laboratory findings, and current research.
It is a thinking and synthesis tool, not a clinical record or formal medical conclusion.

Cross-References

The following documents are part of the master reference system and should be read alongside this document:

• Constitutional CNS Document — the CNS system and its coupling with the gut picture
• Iron Dysbiosis Reference — the iron trigger, collapse mechanism, locked state evidence, personal statement
• Vagal Tone Deficit Mechanistic Reference — the gut-vagus connection in detail, five-factor cumulative vagal deficit
• SetPoint VNS Responder Analysis — Assessment based on truly unknowable response in this system
• Helminthic Therapy Reference — current intervention status and relationship to the gut picture
• Pharmacological Phenotype — amplified medication response pattern, sensitization threshold, PRN constraint, permanently foreclosed agents, clinical safety implications
• Neurological Pattern Reference — HPA axis dysregulation as possible CNS-origin downstream consequence

This document reflects mechanistic relationships and personal hypotheses based on documented history and current research. It is a thinking tool, not a clinical record. 20260520